Journals / Turkish Journal of Urology / 2017 / Cilt: 43 - Sayı: 4

Alternative therapies in patients with non-muscle invasive bladder cancer

Kasa invaze olmamış mesane kanserli hastalarda alternatif tedaviler

Pages
414–424
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, these alternative therapies have been summarized

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide.
📊
Key Findings & Data:Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients.For these patients, some treatment options are readily available and a variety of them are currently underclinical investigation.
💡
Conclusion & Impact:In this review, these alternative therapies have been summarized
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majorityof the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, ithas tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBCis transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG)immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments maybe required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients.For these patients, some treatment options are readily available and a variety of them are currently underclinical investigation. In this review, these alternative therapies have been summarized

Özet

Mesane kanseri tüm dünyada kanser kaynaklı ölümlerin önemli bir nedenidir. Vakaların çoğu daha iyi prognozlu kasa invaze olmayan mesane kanseri (KİOMK) tanısı alsalar da; KİOMK’un nüks etmeye veya daha ileri bir derece veya evreye progrese olma eğilimi vardır. KİOMK’u bulunan hastalarda ilk basamak tedavi transüretral tümör rezeksiyonu ve başta Bacillus-Calmette-Guérin (BCG) immunoterapisi olmak üzere adjuvan tedavilerdir. Ancak BCG başarısızlığı yaşanan hastaların bir kısmında alternatif tedavilere ihtiyaç olabilir. Dahası, intravezikal BCG bir grup hastada kontrendike olabilir; veya tolere edilemeyebilir. Bu hastalarda bazı tedavi seçenekleri halihazırda kullanımda olup, bir kısmı ise klinik araştırma aşamasındadır. Bu derlemede, bu alternatif tedaviler özetlenmiştir.

🔖

Cite This Article

ŞANLI, Ö., LOTAN, Y. (2022). Alternative therapies in patients with non-muscle invasive bladder cancer. Turkish Journal of Urology, Cilt: 43 - Sayı: 4, 414–424. https://ajindex.com/articles/614442

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Harland SJ, Kynaston H, Grigor K, Wallace DM, Beacock C, Kockelbergh R, et al. A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder. J Urol 2007;178:807-13. [CrossRef] Wen J, Zhu X, Liu B, You L, Kong L, Lee HI, et al. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol Immunother 2008;57:1781-94. [CrossRef] Steinberg GD, Shore ND, Karsch LI, Bailen JL, Bivalacqua TJ, Charmie K, et al., editor Immune response results from vesigenurtacel- l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC). ASCO Annual Meeting; 2017 June 02-06, 2017;
  2. Chicago, Ilinois. Keehn A, Gartrell B, Schoenberg MP. Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer. Future Oncol 2016;12:2673-82. [CrossRef] Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312-22. [CrossRef] Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20. [CrossRef] Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, et al. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int 2009;103:978-86. [CrossRef] Mugabe C, Liggins RT, Guan D, Manisali I, Chafeeva I, Brooks DE, et al. Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols. Int J Pharm 2011;404:238-49. [CrossRef] McKiernan JM, Holder DD, Ghandour RA, Barlow LJ, Ahn JJ, Kates M, et al. Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure. J Urol 2014;192:1633-8. [CrossRef] McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette- Guerin refractory nonmuscle invasive bladder cancer. J Urol 2011